I-Mab saw the highest growth of 0.49% in patent filings and no patents were granted in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of I-Mab‘s patent filings and grants. Buy the databook here.
I-Mab has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with three publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 67% of filings. The World Intellectual Property Organization(WIPO), and United States(US) patent Office are among the top ten patent offices where I-Mab is filings its patents..
Regeneron Pharmaceuticals could be the strongest competitor for I-Mab
Patents related to rare diseases lead I-Mab's portfolio
I-Mab has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Breast cancer related patents lead I-Mab portfolio followed by leukemia, and bladder carcinoma
I-Mab has highest number of patents in breast cancer followed by leukemia, bladder carcinoma, solid tumor, and melanoma.
For comprehensive analysis of I-Mab's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.